eligibility_summary
Eligible participants: adults (≥18) followed at Sacré-Cœur Hospital’s outpatient asthma clinic who received anti-IL-5/IL-5R therapy between 2016–2020. Exclusion criteria: none.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Retrospective observational asthma study evaluating anti-IL-5/IL-5R biologics. Interventions: mepolizumab (humanized IgG1 monoclonal antibody against IL-5 cytokine) and benralizumab (afucosylated humanized IgG1 monoclonal antibody against IL-5 receptor alpha). Mechanisms: mepolizumab neutralizes IL-5, blocking its binding to IL-5R on eosinophils and reducing their maturation, activation, and survival, benralizumab binds IL-5Rα on eosinophils/basophils and induces antibody-dependent cell-mediated cytotoxicity (ADCC), leading to near-complete eosinophil depletion. Targets/pathways: IL-5/IL-5R axis, eosinophils (primary) and basophils (secondary), type 2/eosinophilic airway inflammation.